Patents by Inventor Dhavalkumar D. Patel
Dhavalkumar D. Patel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7972605Abstract: The present invention relates, in general, to vaccines and, in particular, to a modified vaccinia Ankara (MVA) virus, to a composition comprising such a virus and to methods of using same to induce an immune response.Type: GrantFiled: September 10, 2007Date of Patent: July 5, 2011Assignee: Duke UniversityInventors: Dhavalkumar D. Patel, David J. Pickup
-
Publication number: 20100150838Abstract: Methods are provided for evaluating osteoarthritis (OA), for example for diagnosing OA, to confirm a diagnosis of OA, to assess or prognose progression of OA, determining the severity of a subject who has OA, and determining a subject's risk of developing OA in the future, as are arrays and kits that can be used to practice the methods. In particular examples, the method includes determining an amount of activity (such as an amount of protein present or an amount of expression) of OA risk-related molecules, such as soluble vascular adhesion protein 1 (sVAP-1) or interleukin-15 (IL-15). Also provided are methods of identifying one or more compounds that alter the activity of an OA-related molecule, thereby identifying potential anti-osteoarthritis drugs.Type: ApplicationFiled: December 24, 2009Publication date: June 17, 2010Inventors: Shari M. Ling, Lorah Perlee, Velizar T. Tchernev, Serguei Lejnine, Dhavalkumar D. Patel, Luigi Ferrucci, Ming Zhan
-
Patent number: 7662573Abstract: Methods are provided for evaluating osteoarthritis (OA), for example for diagnosing OA, to confirm a diagnosis of OA, to assess or prognose progression of OA, determining the severity of a subject who has OA, and determining a subject's risk of developing OA in the future, as are arrays and kits that can be used to practice the methods. In particular examples, the method includes determining an amount of activity (such as an amount of protein present or an amount of expression) of OA risk-related molecules, such as soluble vascular adhesion protein 1 (sVAP-1) or interleukin-15 (IL-15). Also provided are methods of identifying one or more compounds that alter the activity of an OA-related molecule, thereby identifying potential anti-osteoarthritis drugs.Type: GrantFiled: August 12, 2005Date of Patent: February 16, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Shari M. Ling, Lorah Perlee, Velizar T. Tchernev, Serguei Lejnine, Dhavalkumar D. Patel, Luigi Ferrucci, Ming Zhan
-
Publication number: 20090274723Abstract: The present invention relates, in general, to vaccines and, in particular, to a modified vaccinia Ankara (MVA) virus, to a composition comprising such a virus and to methods of using same to induce an immune response.Type: ApplicationFiled: September 10, 2007Publication date: November 5, 2009Inventors: David J. Pickup, Dhavalkumar D. Patel
-
Publication number: 20080213296Abstract: The present invention relates, in general, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same.Type: ApplicationFiled: September 14, 2004Publication date: September 4, 2008Applicant: DUKE UNIVERSITYInventors: Barton F. Haynes, Dhavalkumar D. Patel, Munir Alam, Hua-Xin Liao
-
Patent number: 7101552Abstract: The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same.Type: GrantFiled: September 24, 2001Date of Patent: September 5, 2006Assignee: Duke UniversityInventors: Barton F. Haynes, Dhavalkumar D. Patel, Munir Alam, Hua-Xin Liao
-
Patent number: 7070787Abstract: The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same.Type: GrantFiled: August 25, 2003Date of Patent: July 4, 2006Assignee: Duke UniversityInventors: Barton F. Haynes, Dhavalkumar D. Patel, Munir Alam, Hua-Xin Liao
-
Patent number: 7041294Abstract: A method of eliciting an immune response against an antigen in a vertebrate subject, the method comprising the steps of providing an antigen-adjuvant composition comprising the antigen and a substantially non-toxic adjuvant molecule having biological activity in mucosal tissues, and administering said antigen-adjuvant composition to the vertebrate subject in a manner such that initial contact occurs in mucosal tissue of the vertebrate subject, whereby an immune response is elicited. Cytokines are preferred adjuvants. Preferred cytokines are interleukin-1?(IL-1?) and interleukin-1? (IL-1?).Type: GrantFiled: June 5, 2001Date of Patent: May 9, 2006Assignee: Duke UniversityInventors: Herman F. Staats, Barton F. Haynes, Dhavalkumar D. Patel, Gregory D. Sempowski
-
Patent number: 7033593Abstract: The invention relates to an immunogen comprising an HIV envelope protein bound to a ligand, which ligand upregulates at least one of the CD4 binding site and the CCR5 binding site on the protein, and bound to an HR-2 peptide. The invention also relates to a method of inducing anti-HIV antibodies using such an immunogen.Type: GrantFiled: September 17, 2003Date of Patent: April 25, 2006Assignee: Duke UniversityInventors: Barton F. Haynes, Dhavalkumar D. Patel, Munir Alam, Hua-Xin Liao
-
Publication number: 20040132010Abstract: The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same.Type: ApplicationFiled: September 17, 2003Publication date: July 8, 2004Applicant: DUKE UNIVERSITYInventors: Barton F. Haynes, Dhavalkumar D. Patel, Munir Alam, Hua-Xin Liao
-
Publication number: 20040101510Abstract: We measured the levels of 78 different cytokines and growth factors in culture supernatants to determine the cytokine profiles of cells treated with PARC. We found that specific cytokines were suppressed by PARC. PARC can be used to treat diseases such as cancer, autoimmune diseases, rheumatoid arthritis, myeloproliferative disorders, and coronary artery disease, which are characterized by too much mitosis.Type: ApplicationFiled: September 12, 2003Publication date: May 27, 2004Applicant: Molecular Staging Inc.Inventors: Qin Fu, Velizar T. Tchernev, Ebenezer Satyaraj, Dhavalkumar D. Patel, Stephen F. Kingsmore
-
Publication number: 20040039172Abstract: The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same.Type: ApplicationFiled: August 25, 2003Publication date: February 26, 2004Applicant: DUKE UNIVERSITYInventors: Barton F. Haynes, Dhavalkumar D. Patel, Munir Alam, Hua-Xin Liao
-
Publication number: 20040009503Abstract: Human extracellular ribonucleases (RNases) are widely distributed in various organs and body fluids and together with other members of the mammalian RNase A superfamily. In addition to their RNase activity, several RNases have been shown to have special biological actions, i.e., antitumor, antiviral and angiogenic properties. However, the molecular mechanisms of such activities are unclear. Using protein microarrays amplified rolling circle amplification (RCA), we investigated the effects of EDN (Rnase 2), ECP (Rnase 3) and RNase 1 on leukocytes cytokine production. We measured the levels of 78 different cytokines and growth factors in culture supernatants to determine the cytokine profiles of cells treated with different combinations of RNases and RNase inhibitors.Type: ApplicationFiled: March 26, 2003Publication date: January 15, 2004Applicant: Molecular Staging, Inc.Inventors: Qin Fu, Velizar Tchernev, Ebenezer Satyaraj, Dhavalkumar D. Patel, Stephen F. Kingsmore, Barry Schweitzer
-
Publication number: 20020086283Abstract: The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same.Type: ApplicationFiled: September 24, 2001Publication date: July 4, 2002Inventors: Barton F. Haynes, Dhavalkumar D. Patel, Munir Alam, Hua-Xin Liao
-
Publication number: 20020052318Abstract: The present invention relates, in general, to an adjuvant and, in particular, to an adjuvant that induces durable systemic and mucosal humoral, Th and/or CTL responses. The invention further relates to a composition, e.g., an immunogenic composition, comprising an immunogen and the adjuvant of the invention, and to a method of enhancing an immune response to an immunogen or immunogens using such an adjuvant.Type: ApplicationFiled: August 27, 2001Publication date: May 2, 2002Applicant: DUKE UNIVERSITYInventors: Barton F. Haynes, Hua-Xin Liao, Dhavalkumar D. Patel
-
Publication number: 20010041180Abstract: A method of eliciting an immune response against an antigen in a vertebrate subject, the method comprising the steps of providing an antigen-adjuvant composition comprising the antigen and a substantially non-toxic adjuvant molecule having biological activity in mucosal tissues, and administering said antigen-adjuvant composition to the vertebrate subject in a manner such that initial contact occurs in mucosal tissue of the vertebrate subject, whereby an immune response is elicited. Cytokines are preferred adjuvants. Preferred cytokines are interleukin-1&agr; (IL-1&agr;) and interleukin-1&bgr; (IL-1&bgr;).Type: ApplicationFiled: June 5, 2001Publication date: November 15, 2001Inventors: Herman F. Staats, Barton F. Haynes, Dhavalkumar D. Patel, Gregory D. Sempowski
-
Patent number: 6270758Abstract: A method of eliciting an immune response against an antigen in a vertebrate subject, the method comprising the steps of providing an antigen-adjuvant composition comprising the antigen and a substantially non-toxic adjuvant molecule having biological activity in mucosal tissues, and administering said antigen-adjuvant composition to the vertebrate subject in a manner such that initial contact occurs in mucosal tissue of the vertebrate subject, whereby an immune response is elicited. Cytokines are preferred adjuvants. Preferred cytokines are interleukin-1&agr; (IL-1&agr;) and interleukin-1&bgr; (IL-1&bgr;).Type: GrantFiled: October 8, 1998Date of Patent: August 7, 2001Assignee: Duke UniversityInventors: Herman F. Staats, Barton F. Haynes, Dhavalkumar D. Patel, Gregory D. Sempowski
-
Patent number: 5998172Abstract: The present invention relates, in general, to CD6 and, in particular, to a CD6 ligand present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cell types. The invention further relates to methods of inhibiting the interaction of CD6 and the CD6 ligand, and to methods of screening compounds for their ability to inhibit that interaction. The invention also relates to antibodies, and binding fragments thereof, specific for CD6 ligand.Type: GrantFiled: July 18, 1996Date of Patent: December 7, 1999Assignees: Duke University, Bristol-Myers Squibb CompanyInventors: Barton F. Haynes, Alejandro Aruffo, Dhavalkumar D. Patel, Michael A. Bowen, Hans Marquardt, Anthony W. Siadak
-
Patent number: 5443964Abstract: The invention comprises a plasmid vector, utilizing genetic material that causes high levels of expression of poxvirus genes, and the method of using this genetic material. One preferred embodiment comprises an upstream cis-acting element of a poxvirus gene encoding the major protein component of the poxvirus A-type inclusion. A second preferred embodiment of the invention comprises a downstream cis-acting element of a poxvirus gene encoding the major protein component of the poxvirus A-type inclusion. These elements are inserted upstream and downstream respectively, of selected cloned genes in the plasmid vector to obtain very high levels of expression of the cloned gene.Type: GrantFiled: August 10, 1987Date of Patent: August 22, 1995Assignee: Duke UniversityInventors: David J. Pickup, Dhavalkumar D. Patel